TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

Clinicaltrials.gov identifier:
NCT04821622

Treatment:

Prostate

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Clinicaltrials.gov identifier:
NCT03462342

Treatment:

Ovarian

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04267939

Treatment:

Ovarian, Breast, Pancreatic

Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab)

Clinicaltrials.gov identifier:
NCT04584255

Treatment:

Breast

Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment:

Breast, Ovarian, Pancreatic, Prostate

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib

Clinicaltrials.gov identifier:
NCT03337087

Treatment:

Colorectal, Pancreatic

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

Clinicaltrials.gov identifier:
NCT02286687

Treatment:

Breast, Ovarian, Pancreatic, Prostate

TALAPRO-2: A Study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

Clinicaltrials.gov identifier:
NCT03395197

Treatment:

Prostate

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-(L)1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment:

Colorectal, Endometrial, Pancreatic

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

Clinicaltrials.gov identifier:
NCT03043313

Treatment:

Colorectal

Understanding the Experiences of Black Women after Cancer Genetic Testing

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

Clinicaltrials.gov identifier:
NCT04379999

Prevention:

Colorectal

Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

Clinicaltrials.gov identifier:
NCT03685331

Treatment:

Breast

Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention:

Prostate

Fear of Recurrence, Adversity, and Pain

Breast and Ovarian Cancer Education Research for African American/Black and Latina Women

Prevention:

Breast

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention:

Pancreatic

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention:

Ovarian

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

Clinicaltrials.gov identifier:
NCT04493060

Treatment:

Pancreatic

AMPLIFY: a new online weight loss study specifically for cancer survivors!

Clinicaltrials.gov identifier:
NCT04000880

Quality of Life:

Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor

Developing a Test for the Detection of Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04794322

Prevention:

Ovarian

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Clinicaltrials.gov identifier:
NCT04995198

Using TAS-117 to Treat Advanced Solid Tumors with Inherited PTEN Mutations

Clinicaltrials.gov identifier:
NCT04770246

Treatment:

Breast, Colorectal, Endometrial

Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)

Clinicaltrials.gov identifier:
NCT02997228

Treatment:

Colorectal

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

Clinicaltrials.gov identifier:
NCT04191135

Treatment:

Breast

TALAVE: Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Clinicaltrials.gov identifier:
NCT03964532

Treatment:

Breast

COVID-19 Breast Cancer Care Survey

Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation

Clinicaltrials.gov identifier:
NCT02478892

Prevention:

Pancreatic

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

Clinicaltrials.gov identifier:
NCT03831698

Prevention:

Colorectal

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment:

Pancreatic

Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations

Prevention:

Breast, Ovarian, Pancreatic, Prostate

Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT04115306

Treatment:

Breast

Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04214067

Treatment:

Endometrial

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Clinicaltrials.gov identifier:
NCT04042831

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention:

Ovarian

Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Clinicaltrials.gov identifier:
NCT04008030

Treatment:

Colorectal

A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People with Advanced Pancreatic Cancer and BRCA Mutations

Clinicaltrials.gov identifier:
NCT04150042

Treatment:

Pancreatic

Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Clinicaltrials.gov identifier:
NCT04666740

Treatment:

Pancreatic

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life:

Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor, Pancreatic Cancer Survivor

Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)

Clinicaltrials.gov identifier:
NCT03404960

Treatment:

Pancreatic

Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

Mobile Mindfulness Meditation Intervention for Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life:

Breast Cancer Survivor, Colorectal Cancer Survivor, Endometrial Cancer Survivor, Ovarian Cancer Survivor, Prostate Cancer Survivor, Pancreatic Cancer Survivor

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

TRITON3- Rucaparib vs. Physician Choice for Castration Resistant Prostate Cancer

Clinicaltrials.gov identifier:
NCT02975934

Treatment:

Prostate

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT0823654

Quality of Life:

High Risk But No Cancer, Breast Cancer Survivor

Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations

Clinicaltrials.gov identifier:
NCT03344965

Treatment:

Breast

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

PARP Inhibitor for Metastatic Prostate Cancer With DNA Repair Defects

Clinicaltrials.gov identifier:
NCT03012321

Treatment:

Prostate

Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)

Diagnosis of Breast Cancer in Young Women - Share Your Story

Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment:

Breast

A Study of Nivolumab in Selected Uterine Cancer Patients

Clinicaltrials.gov identifier:
NCT03241745

Treatment:

Endometrial

PARP Inhibitor Alone or Plus Immunotherapy for Advanced BRCA-Associated Breast Cancer

Clinicaltrials.gov identifier:
NCT02849496

Treatment:

Breast

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach)

Clinicaltrials.gov identifier:
NCT04353973

Treatment:

Breast, Ovarian, Pancreatic, Prostate

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Clinicaltrials.gov identifier:
NCT02912559

Treatment:

Colorectal

Genetic Testing for Men with Metastatic Prostate Cancer (GENTleMEN Study)

Clinicaltrials.gov identifier:
NCT03503097

Treatment:

Prostate

Metastatic Prostate Cancer Project

Genetic Education for Men (GEM Study)

Clinicaltrials.gov identifier:
NCT02957981

Prevention:

Prostate

The Metastatic Breast Cancer Project

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

Clinicaltrials.gov identifier:
NCT03327103

Treatment:

Prostate

Quality of Life:

Prostate Cancer Survivor

Pancreatic Cancer Screening Study for High Risk People

Clinicaltrials.gov identifier:
NCT03250078

Prevention:

Pancreatic

Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Clinicaltrials.gov identifier:
NCT04067726

Prevention:

Breast

Connect My Variant

Study of Safety and Effectiveness of Motiva® Breast Implants

Clinicaltrials.gov identifier:
NCT03579901

Quality of Life:

High Risk But No Cancer, Breast Cancer Survivor

Study for People with Unexpected Genetic Results

Clinicaltrials.gov identifier:
NCT02595957

Prevention:

Breast, Ovarian, Pancreatic, Prostate

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes

Clinicaltrials.gov identifier:
NCT04171700

Treatment:

Breast, Ovarian, Pancreatic, Prostate, Endometrial

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Clinicaltrials.gov identifier:
NCT03572374

Quality of Life:

Breast Cancer Survivor

Breast Cancer Treatment in Women with PALB2 Mutations

ELLIE's Project

Quality of Life:

High Risk But No Cancer, Breast Cancer Survivor, Ovarian Cancer Survivor, Pancreatic Cancer Survivor, Melanoma Cancer Survivor

INTERVAL: INTense Exercise foR surVivAL in Men With Metastatic Prostate Cancer

Clinicaltrials.gov identifier:
NCT02730338

Quality of Life:

Prostate Cancer Survivor

RADCOMP: A Study at the Heart of Breast Cancer Treatment

Clinicaltrials.gov identifier:
NCT02603341

Treatment:

Breast

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

Find My Variant

IMPRES - Improving Memory after RRSO

Clinicaltrials.gov identifier:
NCT03187353

Quality of Life:

High Risk But No Cancer, Breast Cancer Survivor, Ovarian Cancer Survivor

Pancreatic Cancer Early Detection

Clinicaltrials.gov identifier:
NCT02206360

Prevention:

Pancreatic

WISDOM Study

Clinicaltrials.gov identifier:
NCT02620852

Prevention:

Breast

PROMPT

Clinicaltrials.gov identifier:
NCT02665195

Serum Folate in Patients Treated with Olaparib

Clinicaltrials.gov identifier:
NCT04024254

Treatment:

Breast, Ovarian

Talazoparib Beyond BRCA (TBB) Trial

Clinicaltrials.gov identifier:
NCT02401347

Treatment:

Breast